Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16483989 | 0.91 | ALDH1A1 (0.47) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL1121142 | 0.87 | ALDH1A1 (0.44) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL4399532 | 0.82 | ALDH1A1 (0.48) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL14208894 | 0.80 | TDP1 (0.38) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL77495 | 0.80 | ALDH1A1 (0.70) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL18294910 | 0.79 | ALDH1A1 (0.45) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL28360398 | 0.79 | MAPT (0.52) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL18542238 | 0.79 | HDAC6 (0.46) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL4647647 | 0.77 | ALDH1A1 (0.45) | TDP1ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL229388 | 0.77 | ALDH1A1 (0.45) | TDP1ALDH1A1TSHRMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286583-B | Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor | 山东大学 | 2024-01-30 | — | — | CN | claimed |
| EP-3466943-B1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO LTD (CN) | 2022-12-28 | — | — | EP | claimed |
| CN-115286583-A | Diphenylaminopyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor | 山东大学 | 2022-11-04 | — | — | CN | claimed |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | claimed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | claimed |
| EP-3466943-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2019-04-10 | — | — | EP | claimed |
| CN-106220608-B | Diphenylamino pyrimidine and triaizine compounds, its Pharmaceutical composition and purposes | 安润医药科技（苏州）有限公司 | 2018-11-27 | — | — | CN | claimed |
| CN-106220608-A | Diphenylamino pyrimidine and triaizine compounds, its Pharmaceutical composition and purposes | 张柏 | 2016-12-14 | — | — | CN | claimed |
| US-20260146084-A1 | METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS | DISC MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-116157403-B | Morphology of treasiril and method for producing same | 海南先声再明医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119325475-A | Bicyclic substituted glutarimide cereblon binders | C4医药公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-115279370-B | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20150280139-A1 | FLUORANTHENE DERIVATIVE, LIGHT-EMITTING DEVICE MATERIAL CONTAINING SAME, AND LIGHT-EMITTING DEVICE | TORAY INDUSTRIES, INC. (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2907803-A1 | FLUORANTHENE DERIVATIVE, LUMINESCENT ELEMENT MATERIAL CONTAINING SAME, AND LUMINESCENT ELEMENT | Toray Industries, Inc. (JP) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057874-A1 | FLUORANTHENE DERIVATIVE, LUMINESCENT ELEMENT MATERIAL CONTAINING SAME, AND LUMINESCENT ELEMENT | 東レ株式会社 (JP) | 2014-04-17 | — | — | WO | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | TDP1 1144/4885ALDH1A1 2069/4885TSHR 341/4885 |
| US-20150280139-A1 | FLUORANTHENE DERIVATIVE, LIGHT-EMITTING DEVICE MATERIAL CONTAINING SAME, AND LIGHT-EMITTING DEVICE | FMNL1, AFF2, LEF1 | TDP1 2458/4885ALDH1A1 1031/4885TSHR 4531/4885 |
| US-20260146084-A1 | METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS | HAMP, BMP6, BMP1 | TDP1 4774/4885ALDH1A1 4567/4885TSHR 503/4885 |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | TDP1 1971/4885ALDH1A1 523/4885TSHR 896/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | TDP1 1144/4885ALDH1A1 2069/4885TSHR 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.